Risk assessment of skin lightening cosmetics containing hydroquinone

Mariko Matsumoto, Hiroaki Todo, Takumi Akiyama, Mutsuko Hirata-Koizumi, Kenji Sugibayashi, Yoshiaki Ikarashi, Atsushi Ono, Akihiko Hirose, Kazuhito Yokoyama

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Following reports on potential risks of hydroquinone (HQ), HQ for skin lightening has been banned or restricted in Europe and the US. In contrast, HQ is not listed as a prohibited or limited ingredient for cosmetic use in Japan, and many HQ cosmetics are sold without restriction. To assess the risk of systemic effects of HQ, we examined the rat skin permeation rates of four HQ (0.3%, 1.0%, 2.6%, and 3.3%) cosmetics. The permeation coefficients ranged from 1.2 × 10−9 to 3.1 × 10−7 cm/s, with the highest value superior than the HQ aqueous solution (1.6 × 10−7 cm/s). After dermal application of the HQ cosmetics to rats, HQ in plasma was detected only in the treatment by highest coefficient cosmetic. Absorbed HQ levels treated with this highest coefficient cosmetic in humans were estimated by numerical methods, and we calculated the margin of exposure (MOE) for the estimated dose (0.017 mg/kg-bw/day in proper use) to a benchmark dose for rat renal tubule adenomas. The MOE of 559 is judged to be in a range safe for the consumer. However, further consideration may be required for regulation of cosmetic ingredients.

Original languageEnglish
Pages (from-to)128-135
Number of pages8
JournalRegulatory Toxicology and Pharmacology
Volume81
DOIs
Publication statusPublished - Nov 1 2016
Externally publishedYes

Fingerprint

Cosmetics
Risk assessment
Skin
Rats
Permeation
hydroquinone
Benchmarking
Adenoma
Numerical methods
Japan
Kidney
Plasmas

Keywords

  • Benchmark dose
  • Dermal absorption
  • Hydroquinone
  • Margin of exposure
  • Permeation coefficients
  • Risk assessment

ASJC Scopus subject areas

  • Toxicology

Cite this

Matsumoto, M., Todo, H., Akiyama, T., Hirata-Koizumi, M., Sugibayashi, K., Ikarashi, Y., ... Yokoyama, K. (2016). Risk assessment of skin lightening cosmetics containing hydroquinone. Regulatory Toxicology and Pharmacology, 81, 128-135. https://doi.org/10.1016/j.yrtph.2016.08.005

Risk assessment of skin lightening cosmetics containing hydroquinone. / Matsumoto, Mariko; Todo, Hiroaki; Akiyama, Takumi; Hirata-Koizumi, Mutsuko; Sugibayashi, Kenji; Ikarashi, Yoshiaki; Ono, Atsushi; Hirose, Akihiko; Yokoyama, Kazuhito.

In: Regulatory Toxicology and Pharmacology, Vol. 81, 01.11.2016, p. 128-135.

Research output: Contribution to journalArticle

Matsumoto, M, Todo, H, Akiyama, T, Hirata-Koizumi, M, Sugibayashi, K, Ikarashi, Y, Ono, A, Hirose, A & Yokoyama, K 2016, 'Risk assessment of skin lightening cosmetics containing hydroquinone', Regulatory Toxicology and Pharmacology, vol. 81, pp. 128-135. https://doi.org/10.1016/j.yrtph.2016.08.005
Matsumoto M, Todo H, Akiyama T, Hirata-Koizumi M, Sugibayashi K, Ikarashi Y et al. Risk assessment of skin lightening cosmetics containing hydroquinone. Regulatory Toxicology and Pharmacology. 2016 Nov 1;81:128-135. https://doi.org/10.1016/j.yrtph.2016.08.005
Matsumoto, Mariko ; Todo, Hiroaki ; Akiyama, Takumi ; Hirata-Koizumi, Mutsuko ; Sugibayashi, Kenji ; Ikarashi, Yoshiaki ; Ono, Atsushi ; Hirose, Akihiko ; Yokoyama, Kazuhito. / Risk assessment of skin lightening cosmetics containing hydroquinone. In: Regulatory Toxicology and Pharmacology. 2016 ; Vol. 81. pp. 128-135.
@article{be676bb4e76d47da923e335deb9432da,
title = "Risk assessment of skin lightening cosmetics containing hydroquinone",
abstract = "Following reports on potential risks of hydroquinone (HQ), HQ for skin lightening has been banned or restricted in Europe and the US. In contrast, HQ is not listed as a prohibited or limited ingredient for cosmetic use in Japan, and many HQ cosmetics are sold without restriction. To assess the risk of systemic effects of HQ, we examined the rat skin permeation rates of four HQ (0.3{\%}, 1.0{\%}, 2.6{\%}, and 3.3{\%}) cosmetics. The permeation coefficients ranged from 1.2 × 10−9 to 3.1 × 10−7 cm/s, with the highest value superior than the HQ aqueous solution (1.6 × 10−7 cm/s). After dermal application of the HQ cosmetics to rats, HQ in plasma was detected only in the treatment by highest coefficient cosmetic. Absorbed HQ levels treated with this highest coefficient cosmetic in humans were estimated by numerical methods, and we calculated the margin of exposure (MOE) for the estimated dose (0.017 mg/kg-bw/day in proper use) to a benchmark dose for rat renal tubule adenomas. The MOE of 559 is judged to be in a range safe for the consumer. However, further consideration may be required for regulation of cosmetic ingredients.",
keywords = "Benchmark dose, Dermal absorption, Hydroquinone, Margin of exposure, Permeation coefficients, Risk assessment",
author = "Mariko Matsumoto and Hiroaki Todo and Takumi Akiyama and Mutsuko Hirata-Koizumi and Kenji Sugibayashi and Yoshiaki Ikarashi and Atsushi Ono and Akihiko Hirose and Kazuhito Yokoyama",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.yrtph.2016.08.005",
language = "English",
volume = "81",
pages = "128--135",
journal = "Regulatory Toxicology and Pharmacology",
issn = "0273-2300",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Risk assessment of skin lightening cosmetics containing hydroquinone

AU - Matsumoto, Mariko

AU - Todo, Hiroaki

AU - Akiyama, Takumi

AU - Hirata-Koizumi, Mutsuko

AU - Sugibayashi, Kenji

AU - Ikarashi, Yoshiaki

AU - Ono, Atsushi

AU - Hirose, Akihiko

AU - Yokoyama, Kazuhito

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Following reports on potential risks of hydroquinone (HQ), HQ for skin lightening has been banned or restricted in Europe and the US. In contrast, HQ is not listed as a prohibited or limited ingredient for cosmetic use in Japan, and many HQ cosmetics are sold without restriction. To assess the risk of systemic effects of HQ, we examined the rat skin permeation rates of four HQ (0.3%, 1.0%, 2.6%, and 3.3%) cosmetics. The permeation coefficients ranged from 1.2 × 10−9 to 3.1 × 10−7 cm/s, with the highest value superior than the HQ aqueous solution (1.6 × 10−7 cm/s). After dermal application of the HQ cosmetics to rats, HQ in plasma was detected only in the treatment by highest coefficient cosmetic. Absorbed HQ levels treated with this highest coefficient cosmetic in humans were estimated by numerical methods, and we calculated the margin of exposure (MOE) for the estimated dose (0.017 mg/kg-bw/day in proper use) to a benchmark dose for rat renal tubule adenomas. The MOE of 559 is judged to be in a range safe for the consumer. However, further consideration may be required for regulation of cosmetic ingredients.

AB - Following reports on potential risks of hydroquinone (HQ), HQ for skin lightening has been banned or restricted in Europe and the US. In contrast, HQ is not listed as a prohibited or limited ingredient for cosmetic use in Japan, and many HQ cosmetics are sold without restriction. To assess the risk of systemic effects of HQ, we examined the rat skin permeation rates of four HQ (0.3%, 1.0%, 2.6%, and 3.3%) cosmetics. The permeation coefficients ranged from 1.2 × 10−9 to 3.1 × 10−7 cm/s, with the highest value superior than the HQ aqueous solution (1.6 × 10−7 cm/s). After dermal application of the HQ cosmetics to rats, HQ in plasma was detected only in the treatment by highest coefficient cosmetic. Absorbed HQ levels treated with this highest coefficient cosmetic in humans were estimated by numerical methods, and we calculated the margin of exposure (MOE) for the estimated dose (0.017 mg/kg-bw/day in proper use) to a benchmark dose for rat renal tubule adenomas. The MOE of 559 is judged to be in a range safe for the consumer. However, further consideration may be required for regulation of cosmetic ingredients.

KW - Benchmark dose

KW - Dermal absorption

KW - Hydroquinone

KW - Margin of exposure

KW - Permeation coefficients

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=84982221075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982221075&partnerID=8YFLogxK

U2 - 10.1016/j.yrtph.2016.08.005

DO - 10.1016/j.yrtph.2016.08.005

M3 - Article

VL - 81

SP - 128

EP - 135

JO - Regulatory Toxicology and Pharmacology

JF - Regulatory Toxicology and Pharmacology

SN - 0273-2300

ER -